Table 1 |
|||
|
The characteristics of samples |
|||
|
Clinical characteristics |
Measure |
Training data |
Testing data |
|
|
|||
|
Number of samples |
85 |
83 |
|
|
|
|||
|
Number of samples in stage III |
71 |
68 |
|
|
|
|||
|
Number of samples in stage IV |
14 |
15 |
|
|
|
|||
|
min. |
36 |
34 |
|
|
Ages (years old) |
medium |
58 |
59 |
|
max. |
87 |
81 |
|
|
|
|||
|
25th percentile |
238 |
283.25 |
|
|
PFS (days) |
median |
396 |
458 |
|
75th percentile |
618.25 |
684 |
|
|
|
|||
|
Number of samples with censored observation |
14 |
22 |
|
|
|
|||
|
Treatment |
paclitaxel carboplatin |
paclitaxel carboplatin other drugs |
|
|
|
|||
|
The clinical characteristics of the training samples and the testing samples. |
|||
|
Hsu et al. BMC Genomics 2012 13(Suppl 6):S13 doi:10.1186/1471-2164-13-S6-S13 |
|||
